SWOG Cancer Research Network
@swog.org
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
Our @swog.org group chair's Front Line blog:
Thank You
Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research.
www.swog.org/news-events/...
Thank You
Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research.
www.swog.org/news-events/...
November 28, 2025 at 5:55 PM
Our @swog.org group chair's Front Line blog:
Thank You
Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research.
www.swog.org/news-events/...
Thank You
Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
CAR-T Cells in Solid Tumors: Challenges and Breakthroughs
doi.org/10.1016/j.xc...
CAR-T Cells in Solid Tumors: Challenges and Breakthroughs
doi.org/10.1016/j.xc...
November 28, 2025 at 5:51 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
CAR-T Cells in Solid Tumors: Challenges and Breakthroughs
doi.org/10.1016/j.xc...
CAR-T Cells in Solid Tumors: Challenges and Breakthroughs
doi.org/10.1016/j.xc...
Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm
November 26, 2025 at 2:25 PM
Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm
S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0/cT1) allow for bladder preservation?
Systematic biopsies needed at post-NAT TURBT pre-registration.
Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center
swog.org/clinical-trials/S2427
Systematic biopsies needed at post-NAT TURBT pre-registration.
Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center
swog.org/clinical-trials/S2427
November 25, 2025 at 2:40 PM
S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0/cT1) allow for bladder preservation?
Systematic biopsies needed at post-NAT TURBT pre-registration.
Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center
swog.org/clinical-trials/S2427
Systematic biopsies needed at post-NAT TURBT pre-registration.
Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center
swog.org/clinical-trials/S2427
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD - Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD - Yale Cancer Center
swog.org/clinical-trials/S2409
November 24, 2025 at 6:20 PM
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD - Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD - Yale Cancer Center
swog.org/clinical-trials/S2409
Our @swog.org group chair's Front Line blog:
SWOG Is All Over ASH 2025
#ASH25 will feature a sizeable group of posters and presentations reporting on (or responding to) SWOG research. Here are some highlights.
www.swog.org/news-events/...
SWOG Is All Over ASH 2025
#ASH25 will feature a sizeable group of posters and presentations reporting on (or responding to) SWOG research. Here are some highlights.
www.swog.org/news-events/...
SWOG Is All Over ASH 2025 | SWOG
If you’re heading to Orlando for the 2025 ASH Annual Meeting and Exposition in the second week of December, and you’re aiming to check out everything SWOG has to offer, you’ll have your work cut out f...
www.swog.org
November 24, 2025 at 3:28 PM
Our @swog.org group chair's Front Line blog:
SWOG Is All Over ASH 2025
#ASH25 will feature a sizeable group of posters and presentations reporting on (or responding to) SWOG research. Here are some highlights.
www.swog.org/news-events/...
SWOG Is All Over ASH 2025
#ASH25 will feature a sizeable group of posters and presentations reporting on (or responding to) SWOG research. Here are some highlights.
www.swog.org/news-events/...
Consider S2427 BRIGHT for your pts with #MIBC getting neoadj therapy. If systematic biopsies at post-NAT TURBT show cT0 or cT1, pt may be eligible for S2427. Can IO + RT be bladder-preserving? #BladderCancer
PI: Leslie Ballas, MD Cedars-Sinai Cancer
swog.org/clinical-trials/S2427
PI: Leslie Ballas, MD Cedars-Sinai Cancer
swog.org/clinical-trials/S2427
November 22, 2025 at 4:35 PM
Consider S2427 BRIGHT for your pts with #MIBC getting neoadj therapy. If systematic biopsies at post-NAT TURBT show cT0 or cT1, pt may be eligible for S2427. Can IO + RT be bladder-preserving? #BladderCancer
PI: Leslie Ballas, MD Cedars-Sinai Cancer
swog.org/clinical-trials/S2427
PI: Leslie Ballas, MD Cedars-Sinai Cancer
swog.org/clinical-trials/S2427
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Bispecific Antibodies and Nanotechnology: A Strategic Alliance in Cancer Immunotherapy
doi.org/10.1186/s129...
Bispecific Antibodies and Nanotechnology: A Strategic Alliance in Cancer Immunotherapy
doi.org/10.1186/s129...
Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy - Molecular Cancer
Bispecific antibodies (bsAbs), designed to recognize two distinct antigens or epitopes, enable innovative mechanisms of action for emerging generations of cancer immunotherapies. Despite their potenti...
doi.org
November 21, 2025 at 6:01 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Bispecific Antibodies and Nanotechnology: A Strategic Alliance in Cancer Immunotherapy
doi.org/10.1186/s129...
Bispecific Antibodies and Nanotechnology: A Strategic Alliance in Cancer Immunotherapy
doi.org/10.1186/s129...
Reposted by SWOG Cancer Research Network
You have a great research idea? A critical need to address? Let's tackle it together.
We agree:
"...while Hope is often referred to as SWOG’s public charity, it has become so, so much more."
We're honored to help advance #SWOGonc research & grateful to all who make it possible.
Thank you!
We agree:
"...while Hope is often referred to as SWOG’s public charity, it has become so, so much more."
We're honored to help advance #SWOGonc research & grateful to all who make it possible.
Thank you!
Our @swog.org group chair's Front Line blog:
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
This Thanksgiving, It’s All About Hope | SWOG
Thanksgiving is still a couple of weeks out, but it’s never too early to count our blessings.
www.swog.org
November 18, 2025 at 7:02 PM
You have a great research idea? A critical need to address? Let's tackle it together.
We agree:
"...while Hope is often referred to as SWOG’s public charity, it has become so, so much more."
We're honored to help advance #SWOGonc research & grateful to all who make it possible.
Thank you!
We agree:
"...while Hope is often referred to as SWOG’s public charity, it has become so, so much more."
We're honored to help advance #SWOGonc research & grateful to all who make it possible.
Thank you!
Our @swog.org group chair's Front Line blog:
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
This Thanksgiving, It’s All About Hope | SWOG
Thanksgiving is still a couple of weeks out, but it’s never too early to count our blessings.
www.swog.org
November 14, 2025 at 6:32 PM
Our @swog.org group chair's Front Line blog:
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
**This Thanksgiving, It's All About Hope**
Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD:
Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors
academic.oup.com/narcancer/ar...
Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors
academic.oup.com/narcancer/ar...
November 14, 2025 at 6:26 PM
Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD:
Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors
academic.oup.com/narcancer/ar...
Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors
academic.oup.com/narcancer/ar...
Reposted by SWOG Cancer Research Network
Supporting Veterans with Access to Better Care
10 years of our @swog.org VA Integration and Storefront grant programs #SWOGonc
conta.cc/43SSei3
10 years of our @swog.org VA Integration and Storefront grant programs #SWOGonc
conta.cc/43SSei3
November 11, 2025 at 10:06 PM
Supporting Veterans with Access to Better Care
10 years of our @swog.org VA Integration and Storefront grant programs #SWOGonc
conta.cc/43SSei3
10 years of our @swog.org VA Integration and Storefront grant programs #SWOGonc
conta.cc/43SSei3
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
November 7, 2025 at 7:33 PM
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT signaling in cancer: molecular mechanisms and potential therapies - Molecular Biomedicine
The WNT signaling pathway, a fundamental molecular network regulating cell proliferation, differentiation, and stemness, plays a critical role in tumorigenesis, cancer progression, and therapeutic res...
doi.org
November 7, 2025 at 5:01 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies
doi.org/10.1186/s435...
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
November 6, 2025 at 5:02 PM
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
November 4, 2025 at 12:53 PM
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
October 31, 2025 at 4:21 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
October 27, 2025 at 3:46 PM
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions - Molecular Cancer
Cancer cells express high levels of programmed cell death-ligand 1 (PD-L1) to evade immune surveillance. PD-L1 interacts with PD-1 on T cells to make them non-functional. Thus, PD-L1 and PD-1 are pivo...
doi.org
October 27, 2025 at 3:35 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions
doi.org/10.1186/s129...
Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer:
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors ...
Background Malignant perivascular epithelioid cell tumors (PEComas) are ultra-rare, aggressive mesenchymal neoplasms associated with poor outcomes. Standard-of-care systemic therapy includes mammalian...
jitc.bmj.com
October 22, 2025 at 12:58 PM
Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer:
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Reposted by SWOG Cancer Research Network
From the @swog.org Front Line:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan | SWOG
Today, I’m excited to discuss our next myeloma committee chair, Dr. Amrita Y. Krishnan, who will formally step into the role on November 1st (I briefly welcomed her at plenary in Chicago – this is my ...
www.swog.org
October 20, 2025 at 4:34 PM
From the @swog.org Front Line:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
#SWOGonc
www.swog.org/news-events/...
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
October 17, 2025 at 8:35 PM
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
October 17, 2025 at 3:52 PM
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
October 17, 2025 at 3:50 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Reposted by SWOG Cancer Research Network
Team Hope returns to Arizona in March!
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
October 16, 2025 at 3:05 PM
Team Hope returns to Arizona in March!
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj
Riders will again raise funds and support for @swog.org research through participation in the Tour de Scottsdale #SWOGonc
Can you join us? 🚴♂️
conta.cc/4ooJOHj